Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020748 · ClinicalTrials.gov registry record · Phase 1
Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00020748 is a Phase 1 study that has completed, run by Georgetown University.
The verdict
NCT00020748, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of epirubicin plus irinotecan in treating patients who have advanced cancer.
Interventions
- DRUG epirubicin hydrochloride
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020748
The ClinicalTrials.gov registry entry for NCT00020748 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which epirubicin hydrochloride is the first listed.
NCT00020748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020748 about?
NCT00020748 is a clinical study titled "Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of epirubicin plus irinotecan in treating patients who have advanced canc...
What is the current status of trial NCT00020748?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-08. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00020748?
The interventions under investigation include: epirubicin hydrochloride (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00020748?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.